Table 2. Incidence rates and hazard ratios for study outcomes comparing ACEI therapy with ARB therapy.
| Events, No. | Incidence rate per 1000 patient-years | Hazard ratio (95% confidence interval) | ||||
|---|---|---|---|---|---|---|
| Outcome | ACEI | ARB | ACEI | ARB | Crude | Fully adjusted* |
| Long-term dialysis | 975 | 573 | 3.45 | 3.26 | 1.04 (0.93–1.15) | 0.93 (0.83–1.03) |
| Acute kidney injury | 269 | 124 | 0.95 | 0.70 | 1.25 (1.01–1.55)† | 1.07 (0.85–1.35) |
| Hyperkalemia | 1183 | 568 | 4.18 | 3.23 | 1.22 (1.11–1.35)† | 1.02 (0.92–1.14) |
| All-cause death | 263 | 243 | 0.92 | 1.38 | 0.65 (0.54–0.77)† | 1.17 (0.98–1.40) |
| Cardiovascular death | 136 | 120 | 0.48 | 0.68 | 0.68 (0.53–0.87)† | 1.04 (0.80–1.34) |
| Non-cardiovascular death | 127 | 123 | 0.45 | 0.70 | 0.62 (0.48–0.79)† | 1.28 (0.99–1.65) |
* Cox proportional hazards model adjusted for age, sex, cardiovascular disease, chronic kidney disease, hepatic disease, cancer, income, occupation, geographic location, Charlson comorbidity index score, and year of index date.
† P ≤ 0.05.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.